Deep Vein Thrombosis Market Report 2026

The deep vein thrombosis market size has grown steadily in recent years. It will grow from $1.09 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 4%. The growth in the historic period can be attributed to increasing incidence of venous thromboembolism, aging population with sedentary lifestyles, growth in hospital-based surgical procedures, wider availability of conventional anticoagulants, rising awareness of dvt complications.

The deep vein thrombosis market size is expected to see steady growth in the next few years. It will grow to $1.37 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to advancement in novel anticoagulant therapies, increasing preference for oral over injectable treatments, expansion of homecare and remote monitoring, growth in preventive screening programs, improved access through online pharmacies. Major trends in the forecast period include growing adoption of direct oral anticoagulants, shift toward outpatient and home-based dvt management, increased focus on early diagnosis and risk stratification, rising use of minimally invasive interventional procedures, expansion of online and specialty pharmacy channels.

The growing number of individuals requiring treatment for deep vein thrombosis (DVT) is anticipated to drive the expansion of the deep vein thrombosis market in the coming years. DVT treatment involves managing patients diagnosed with deep vein thrombosis through medications such as anticoagulants and other therapies that help prevent the formation of new blood clots and stop existing clots from enlarging, thereby alleviating disease severity. An increase in the number of patients needing DVT treatment reflects a higher prevalence of the condition, which in turn raises demand for products used in the diagnosis, prevention, and treatment of DVT. For example, in February 2023, according to the Centers for Disease Control and Prevention, a US-based national public health agency, nearly 900,000 people may be affected annually by deep vein thrombosis in the United States, with between 60,000 and 100,000 deaths each year attributed to DVT or pulmonary embolism (PE). Therefore, the rising number of individuals requiring DVT treatment is contributing to market growth.

Major companies operating in the deep vein thrombosis market are increasingly adopting strategic partnerships to enable faster diagnosis of DVT and strengthen their market position. These collaborations highlight the growing focus on applying artificial intelligence and machine learning technologies to enhance medical diagnostics, including the rapid and accurate detection of DVT. For instance, in November 2023, ThinkSono Ltd., a UK-based ultrasound AI company specializing in DVT diagnosis, partnered with NYU Langone Health, a US-based academic medical center, to initiate the first clinical trial of an AI-powered ultrasound software designed to enable quicker and more portable diagnosis of deep vein thrombosis. Through this collaboration, the ThinkSono Guidance System leverages AI technology to potentially identify DVT more rapidly, accurately, and cost-effectively than conventional diagnostic methods. In this trial, researchers use the ThinkSono system alongside standard ultrasound scanning in patients both with and without DVT, comparing the performance of the two approaches to validate accuracy. Medical students from the NYU Grossman School of Medicine also participate in conducting the study as part of their practical research training.

In March 2024, Pfizer Inc., a US-based biopharmaceutical company, partnered with Bristol-Myers Squibb to provide grant support for continuing professional education focused on anticoagulation in atrial fibrillation and venous thromboembolism. This partnership encourages organizations to apply for grants supporting independent educational initiatives aimed at improving knowledge and understanding of oral anticoagulant therapies for patients with atrial fibrillation and venous thromboembolism.

Major companies operating in the deep vein thrombosis market are Abbott Laboratories, Bristol-Myers Squibb Company, Sanofi-Aventis U.S. LLC, Daiichi Sankyo Company Limited, Novartis AG, Mylan N.V., Bayer AG, Boehringer Ingelheim GmbH, Medtronic PLC, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd., Stryker Corporation, Cook Medical Incorporated, Boston Scientific Corporation, Pfizer Inc., Johnson & Johnson, GlaxoSmithKline plc, Shire Pharmaceuticals, AstraZeneca PLC, Endo International plc.

North America was the largest region in the deep vein thrombosis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global deep vein thrombosis market report during the forecast period. The regions covered in the deep vein thrombosis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the deep vein thrombosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the deep vein thrombosis market by increasing costs of imported anticoagulants, ivc filters, and medical devices used in diagnosis and treatment, affecting pricing and availability across hospital and retail pharmacy channels. regions reliant on imported pharmaceutical ingredients and devices, particularly asia-pacific and parts of europe, are most affected. drug-based treatment segments and advanced ivc filter systems face the highest pressure. however, tariffs are encouraging local manufacturing, supply chain diversification, and regional production investments, supporting long-term market resilience.

The deep vein thrombosis market research report is one of a series of new reports that provides deep vein thrombosis market statistics, including deep vein thrombosis industry global market size, regional shares, competitors with a deep vein thrombosis market share, detailed deep vein thrombosis market segments, market trends and opportunities, and any further data you may need to thrive in the deep vein thrombosis industry. This deep vein thrombosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Deep vein thrombosis (DVT) is a serious medical condition that occurs when a blood clot develops in one or more of the deep veins of the body. Common symptoms of DVT include swelling, pain, and tenderness in the affected area, most often in the leg.

The primary types of treatments used for deep vein thrombosis include anticoagulants, inferior vena cava filters, and others. Anticoagulants, commonly referred to as blood thinners, are medications used to prevent the formation of blood clots within blood vessels. DVT is managed through approaches such as surgery, medications, and other methods, with various routes of administration including injectable, oral, and others. These treatments are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a range of end users including hospitals, homecare settings, specialty clinics, and others.

The deep vein thrombosis market includes revenues earned by entities by providing services related to treatment such as blood thinning medication, thrombolytic therapy, interventional radiology therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.